2Bondarenko M,Curti C,Montana M,et al.Efficacy andtoxicity of factor Xa inhibitors [J].J Pharm Pharm Sci,2013,16(1): 74-88.
3Genovesi S,Rossi E,Gallieni M,et al.Warfarin use,mortality,bleeding and stroke in haemodialysis patientswith atrial fibrillation [J].Nephrol Dial Transplant,2014,28(8): 1-8.
4Ranganathan R L,Venkatesh P.Atrial fibrillation andstroke prevention: is warfarin still an option?—No.[J].JNeural Transm,2013,120(10): 1453-1456.
5Lee Y K,Player M R.Developments in factor Xainhibitors for the treatment of thromboembolic disorders[J].Med Res Rev,2011,31(2): 202-283.
6Zhang P,Huang W,Wang L,et al.Discovery ofbetrixaban (PRT054021),N-(5-chloropyridin-2-yl)-2-(4-N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide,a highly potent,selective,and orally efficaciousfactor Xa inhibitor [J].Bioorg Med Chem Lett,2009,19(8): 2179-2185.
7Morganroth J,Gretler D D,Hollenbach S J,et al.Absenceof QTc prolongation with betrixaban: a randomized,double-blind,placebo- and positive-controlled thorough ECGstudy [J].Expert Opin Pharmacother,2013,14(1): 5-13.
8Kanter J P,Suizno K,Zuberi S S,et al.Methods ofsynthesizing pharmceutical salts of a factor Xa inhibitor[P].WO: 2008057972 A1,2008-05-15.
9Pandey A,Leitao E P T,Song Z G,et al.Methods ofsynthesizing factor Xa inhibitors [P].WO: 2011084519,2011-07-14.
10Chan N C,Hirsh J,Ginsberg J S,et al.Betrixaban(PRT054021): pharmacology,dose selection and clinicalstudies [J].Future Cardiol,2014,10(1): 43-52.
